Brinker Capital Investments’s MABVAX THERAPEUTICS HLDGS INC MBVX Stock Holding History

Brinker Capital Investments’s Portfolio MBVX Stock Details MBVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-333	Closed	–	–	718
2018 Q2	$0	Hold	333	–	–	﹤0.01%	661
2018 Q1	$1K	Hold	333	–	–	﹤0.01%	523
2017 Q4	$1K	Hold	333	–	–	﹤0.01%	504
2017 Q3	$1K	Buy	+333	New	+$728	﹤0.01%	571

Other funds holding MBVX

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Brinker Capital Investments's MBVX Position: Q3 2018 in Review

Brinker Capital Investments sold out of MABVAX THERAPEUTICS HLDGS INC (MBVX) in Q3 2018, closing a stake of 333 shares.

Brinker Capital Investments first reported a position in MBVX in Q3 2017 and held it in 4 quarters. The position peaked at $1K in Q1 2018. 2 funds tracked by Wall St. Rank hold MBVX as of Q3 2018.

Brinker Capital Investments reported no remaining MABVAX THERAPEUTICS HLDGS INC position as of Q3 2018 after selling out during the quarter.
Brinker Capital Investments sold 333 MABVAX THERAPEUTICS HLDGS INC shares in Q3 2018.
Brinker Capital Investments first reported a position in MABVAX THERAPEUTICS HLDGS INC in Q3 2017 and held it in 4 quarters.
Brinker Capital Investments's MABVAX THERAPEUTICS HLDGS INC position peaked at $1K in Q1 2018.
2 funds tracked by Wall St. Rank held MABVAX THERAPEUTICS HLDGS INC as of Q3 2018.

Based on Brinker Capital Investments's 13F filing for Q3 2018, filed 13 Nov 2018.